PlainRecalls
FDA Drug Critical Class I Ongoing

Ropivacaine Hydrochloride Injection, USP, 0.5%, 500 mg per 100 mL (5mg/mL), Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Mehsana, India, , Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807 NDC 70121-1734-1 (bag); NDC 70121-1734-3 (box)

Reported: May 14, 2025 Initiated: April 17, 2025 #D-0402-2025

Product Description

Ropivacaine Hydrochloride Injection, USP, 0.5%, 500 mg per 100 mL (5mg/mL), Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Mehsana, India, , Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807 NDC 70121-1734-1 (bag); NDC 70121-1734-3 (box)

Reason for Recall

Presence of Particulate Matter

Details

Units Affected
62 (12x100mL) bags
Distribution
Nationwide in the US
Location
Bridgewater, NJ

Frequently Asked Questions

What product was recalled?
Ropivacaine Hydrochloride Injection, USP, 0.5%, 500 mg per 100 mL (5mg/mL), Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Mehsana, India, , Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807 NDC 70121-1734-1 (bag); NDC 70121-1734-3 (box). Recalled by Amneal Pharmaceuticals, LLC. Units affected: 62 (12x100mL) bags.
Why was this product recalled?
Presence of Particulate Matter
Which agency issued this recall?
This recall was issued by the FDA Drug on May 14, 2025. Severity: Critical. Recall number: D-0402-2025.